SanofiXSWX:SAN 87 PB Ratio is 1.33 as of Jun. 27, 2026, which is 17% below its 10-year median of 1.60. GuruFocus rates XSWX:SAN with a GF Score™ of 87/100 and a GF Value™ of CHF104.30. The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Sanofi ranks better than 66.81% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Sanofi's share price is CHF73.20. Sanofi's Book Value per Share for the quarter that ended in Dec. 2025 was CHF55.15. Hence, Sanofi's PB Ratio of today is 1.33.
Good Sign:
Sanofi SA stock PB Ratio (=1.27) is close to 10-year low of 1.24.
The historical rank and industry rank for Sanofi's PB Ratio or its related term are showing as below:
XSWX:SAN'
s PB Ratio Range Over the Past 10 Years
Min: 1.24 Med: 1.6 Max: 2.04
Current: 1.27
During the past 13 years, Sanofi's highest PB Ratio was 2.04. The lowest was 1.24. And the median was 1.60.
XSWX:SAN's PB Ratio is ranked better than 66.81% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs XSWX:SAN: 1.27
During the past 12 months, Sanofi's average Book Value Per Share Growth Rate was -4.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sanofi was 58.60% per year. The lowest was -0.10% per year. And the median was 4.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sanofi PB Ratio Related Terms
Sanofi PB Ratio Historical Data
* Premium members only.
The historical data trend for Sanofi's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Sanofi's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sanofi's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Sanofi's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sanofi (XSWX:SAN) has a PB Ratio of 1.33 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanofi and its competitors. This is 17% below median its historical median of 1.60. Over the past decade, Sanofi's PB Ratio has ranged from 1.24 to 2.04. According to the industry distribution chart, Sanofi ranks #306 out of 922 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Sanofi's PB Ratio too high?
Sanofi's current PB Ratio of 1.33 is 17% below median its 10-year median of 1.60. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 2.04. The Drug Manufacturers industry median PB Ratio is 1.83. Sanofi's value of 1.33 is 27.1% below this industry median. Based on the distribution chart, Sanofi ranks #306 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #306 out of 922 companies for PB Ratio. This puts Sanofi in the upper half of its industry. The industry median PB Ratio is 1.83. Sanofi's value of 1.33 is 27.1% below this benchmark. Historically, Sanofi's own PB Ratio has ranged from 1.24 to 2.04 over the past decade. While the company's 10-year median is 1.60 vs. the industry median of 1.83, Sanofi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current PB Ratio of 1.33 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current PB Ratio is 1.33, which is 17% below median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current PB Ratio of 1.33. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current PB Ratio is 1.33, which is 17% below median its 10-year median of 1.60 and 27.1% below the Drug Manufacturers industry median of 1.83. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current PB Ratio is 1.33 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (XSWX:SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.
Key valuation signals for XSWX:SAN:
PB Ratio: 1.33 (17% below median its 10-year median of 1.60)
GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
Industry Position: 27.1% below the Drug Manufacturers median (#306 of 922)
No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score
Get the complete analysis for XSWX:SAN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SAN has been successfully added to your 
